Dr Matty Moore – Musculoskeletal Chronic Pain Study
Dr Matty Moore – Musculoskeletal Chronic Pain Study aims to examine the safety and feasibility of three Medicinal Cannabis (MC) oil medications for addressing Musculoskeletal (MSK) chronic pain – Primary Outcome.
It will also evaluate the effects of these medications on depression, anxiety, stress, sleep quality, and quality of life and record any adverse events – Secondary Outcomes.
The study will require participants to complete a baseline and then weekly standardised and validated Patient Reported Outcome Measure (PROM) questionnaires to record whether there is a change or improvement whilst using one of these 3 MC oils over 12 weeks or until they cease taking the medication.
Ethics Approval through NIIM has been granted, and the study aims to start recruiting participants in May 2023.
There will be 100 patients recruited for this study. They will have to be seeking treatment for chronic pain of Musculoskeletal origin.
Access the Eligibility Questionnaire and see if you are an eligible participant.
Patients eligible for the study may be prescribed one of three pharmaceutical preparations of the whole plant-extracted cannabis oils products contain various combinations and strengths of CBD and/or THC.
The study will analyse the participant’s self-completed PROM questionnaire data to find significant differences in each primary and secondary outcome under study.
Other de-identified clinical data points collected will include:
- Numbers and severity of Adverse Events considered likely or definitely associated with medicinal cannabis administration.
- Population descriptors
- Health Related Descriptors
- Medical history and comorbidities
- Concomitant medications
- History of previous intolerance or adverse events to medications
It is hoped conclusions will be drawn as to whether or not these particular medications warrant further and more rigorous clinical trial investigation as an interventional treatment for chronic pain in this patient cohort.
Study Design and Coordination – Sharlene Mavor, Associate Researcher
Study Coordination and Data Analysis – Rachel Jaros, Associate Researcher
Disclaimer: This study involves medicinal cannabis products which are not registered on the Australian Register for Therapeutic Goods (ARTG) and can only be accessed via the Special Access Scheme (SAS, category A or B) or the Authorised Prescriber scheme. The prescription of any unregistered product is at the discretion of the prescribing physician.